Trinity Deferred Long Term Liab from 2010 to 2025
| TRIB Stock | USD 0.76 0.01 1.30% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 15.9 M | Current Value 15.1 M | Quarterly Volatility 22.7 M |
Check Trinity Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trinity Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Total Revenue of 78.6 M or Gross Profit of 35.1 M, as well as many indicators such as Price To Sales Ratio of 6.33, Dividend Yield of 5.0E-4 or Days Sales Outstanding of 88.98. Trinity financial statements analysis is a perfect complement when working with Trinity Biotech Valuation or Volatility modules.
Trinity | Deferred Long Term Liab |
Latest Trinity Biotech's Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Trinity Biotech plc over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Trinity Biotech's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Trinity Biotech's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Trinity Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 37,174,540 | |
| Geometric Mean | 31,143,980 | |
| Coefficient Of Variation | 61.11 | |
| Mean Deviation | 19,155,277 | |
| Median | 34,778,000 | |
| Standard Deviation | 22,716,451 | |
| Sample Variance | 516T | |
| Range | 75.8M | |
| R-Value | (0.78) | |
| Mean Square Error | 218.6T | |
| R-Squared | 0.60 | |
| Significance | 0.0004 | |
| Slope | (3,710,154) | |
| Total Sum of Squares | 7740.6T |
Trinity Deferred Long Term Liab History
About Trinity Biotech Financial Statements
Trinity Biotech stakeholders use historical fundamental indicators, such as Trinity Biotech's Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Trinity Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Trinity Biotech's assets and liabilities are reflected in the revenues and expenses on Trinity Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Trinity Biotech plc. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 15.9 M | 15.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:Check out the analysis of Trinity Biotech Correlation against competitors. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (2.25) | Revenue Per Share | Quarterly Revenue Growth 0.032 | Return On Assets |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.